Keratoacanthoma

    La Roche-Posay
  • May 2022
  • 10min

Therapeutic classes inducing this adverse event
BRAF inhibitor, RAF inhibitor

Keratoacanthoma
Well-defined papule with central hyperkeratotic core, eruptive onset
Well-defined papule with central hyperkeratotic core, eruptive onset

Browse for more adverse events